



ASX Announcement and Media Release

Friday, March 4, 2011

SciGen Ltd

CHANGE IN THE BOARD OF DIRECTORS

The Board of Directors of SciGen Limited (ASX: SIE) (the “**SciGen**”) announce changes in the Board.

RESIGNATION OF CFO & DIRECTOR

Following his resignation as CFO, Mr. Martin Cooper had also resigned as a Director of the company. Mr. Cooper leaves to take up a new role as the CFO of another ASX listed company.

The Board thanks Mr. Cooper for his contribution to SciGen and wishes Mr. Cooper well in his future endeavours.

APPOINTMENT OF CFO & DIRECTOR

SciGen is pleased to announce the appointments of Mr. Adam Aleksandrowicz as the CFO and as a Director of the Company.

Mr. Aleksandrowicz, the financial director and member of the Managing Board of Bioton S.A, is a graduate from the University of Gdańsk. He has extensive knowledge and experience in corporate finance management, in particular in companies in pharmaceutical industry. Between 2006-2009 he worked for AstraZeneca, one of the world’s leading pharmaceutical concerns, holding the position of CFO in AstraZeneca’s companies in Poland and in Russia. Prior to this, Mr. Aleksandrowicz was with Pliva Kraków S.A., a subsidiary of TEVA, where he started CFO and progressed to the position of President of the Managing Board. Mr. Aleksandrowicz had also worked as a manager in Corporate Finance in PriceWaterhouseCoopers, Poland, working on mergers and acquisitions, evaluation of businesses, restructuring of companies and optimization of financing structures of company development. Before taking up the work at PriceWaterhouseCoopers he worked as

Corporate Finance consultant at O.M. Investment Sp. z o.o and in investors relations department at Bank Gdański S.A. He has completed a number of postgraduate studies, among others Executive Management Program University of Michigan School of Business Administration in the United States.

SciGen's Chairman, Mr. Ryszard Krauze commented that "The appointment of Mr. Aleksandrowicz to the role of Director in addition to his role of CFO, reflects the respect the Board has for his experience, ability and sound understanding of the Bio-Pharmaceutical Industry."

RESIGNATION OF DIRECTOR

SciGen has today announced that Dr. Marian Gorecki had resigned from the Board of Directors of SciGen after five years. Dr. Gorecki was also the Chairman of the SciGen Scientific Advisory Board and member of the Audit Committee.

On behalf of the Board, Mr Ryszard Krauze, Chairman of SciGen Ltd, thanks Dr. Marian Gorecki for his contribution to SciGen over the years.

About SciGen

SciGen Ltd is a progressive biopharmaceutical company involved in co-developing and marketing genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes a third generation Hepatitis B Vaccine and therapeutics such as rhuman Growth Hormone, rhuman Insulin, GCSF and Interferon Alpha 2b.

SciGen has acquired the rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biosimilar products, which allows for faster entry into the market, as the biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development.

SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's major strength lies in its ability to recognise the potential of new products in their early stages of development. Through joint collaboration with its strategic partners, SciGen uses its extensive expertise in regulatory and clinical environments, in conjunction with marketing and promotional infrastructure, to bring to market products which will have significant long-term benefit.

SciGen's business was established in 1988. SciGen is a Singapore biotechnology company, publicly listed on the Australian Stock Exchange (ASX code SIE). SciGen's headquarters is in Singapore and it also has subsidiary companies and offices in Australia, South Korea, Vietnam, China, India, Israel and Philippines, distribution channels in Taiwan, China, India,

Pakistan, Thailand and Indonesia, manufacturing facilities in Israel, India and China and a contract manufacturer in Poland, Bioton S.A.

For further information: Company - Investor Relations	Company
Ms. Gillian Dunlop SciGen (Australia) Pty Ltd +61 2 9485 1800 Email: gdunlop@scigen.com.au	Slawomir Ziegert CEO SciGen Ltd +65 6779 6638